India approves Anika’s Monovisc osteoarthritis treatment

Anika Therapeutics (NSDQ:ANIK) said today that regulatory authorities in India approved its single injection viscosupplement, Monovisc, as a therapy for pain associated with osteoarthritis in synovial joints.

The Bedford, Mass.-based company’s product is already available in the U.S. Canada and Europe. Anika said it hopes to expand into Australia, New Zealand and other international markets in the next nine months.

Get the full story at our sister site, Drug Delivery Business News.

The post India approves Anika’s Monovisc osteoarthritis treatment appeared first on MassDevice.

from MassDevice http://ift.tt/2uUwTWf